MCL1 and neoplasm: Thus, loss of the LKB1 tumor suppressor is associated with increased MCL-1 dependence upon treatment with sotorasib or trametinib in KRASG12C-mutant NSCLCs, creating an apoptotic vulnerability that can be exploited by concurrent inhibition of MCL-1.